Monitored Anesthesia Care vs. General Anesthesia for Transcatheter Aortic Valve Replacement

Overview

This study is being done to evaluate the impact that monitored anesthetic care (MAC) versus general endotracheal anesthesia (GETA) has on hospital length of stay, rate of ICU admission, and procedural mortality for patients undergoing Transcatheter Aortic Valve Replacement (TAVR). Also, the investigators hope to determine if the use of Transesophageal Echocardiography (TEE) during GETA impacts device success. Adult patients undergoing transfemoral approach TAVR for aortic valve stenosis may be eligible candidates for this study.

Full Title of Study: “A Randomized Controlled Trial Comparing Monitored Anesthesia Care Versus General Anesthesia With Transesophgeal Echocardiography for Transcatheter Aortic Valve Replacement”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: June 30, 2025

Interventions

  • Procedure: General Endotracheal Anesthesia
    • Participants receive general endotracheal anesthesia for the procedure, as well as analyzing the information from their transesophageal echocardiography per routine clinical care.
  • Procedure: Monitored anesthesia care
    • Participants receive monitored anesthesia care for their procedure.

Arms, Groups and Cohorts

  • Active Comparator: General
    • Participants randomized to group A will receive general endotracheal anesthesia as their anesthetic procedure.
  • Active Comparator: Sedation
    • Participants randomized to group B will receive monitored anesthesia care as their anesthetic procedure.

Clinical Trial Outcome Measures

Primary Measures

  • Hospital Length of Stay
    • Time Frame: Up to 1 month
    • The total number of hours that the patient stayed in the hospital will be measured from the “Anesthesia Start” time until their time of discharge, as recorded in their electronic medical record.
  • ICU Admission Rate
    • Time Frame: Up to 48 hours
    • The investigators will determine the ICU admission rate by taking the total number of patients admitted to the ICU and dividing it by the number of cases in each arm of the study, based on MUSC’s “fast track” pathway and our inclusion.
  • Procedural Mortality
    • Time Frame: Up to 30 days
    • The percentage of the study population that died within 30 days of their procedure or during index procedure hospitalization – if the postoperative length of stay is longer than 30 days.

Secondary Measures

  • Paravalvular Regurgitation
    • Time Frame: For GETA cases, will be recorded after valve implantation. For all cases, will be recorded from a TTE report that is completed on post-operative day 1 or 2 and at 1 year.
    • Paravalvular regurgitation is a specific type of aortic regurgitation that is determined qualitatively by the echocardiographer. It is defined as the grade of aortic valve regurgitation around the perimeter of the implanted prosthesis. The assigned grade will be classified according to a unifying five-class scheme, at the determination of the cardiologist. Grade of aortic regurgitation is measured as none, mild, moderate, or severe. None is best, severe is worst. For GETA cases, paravalvular regurgitation will be recorded after valve implantation by the anesthesiologist performing TEE, as is routine. For all cases, paravalvular regurgitation will be recorded from a TTE report that is completed on post-operative day 1 or 2 (the 1st post-operative TTE) during routine clinical care, and again by TTE report at 1 year during routine clinical follow-up.

Participating in This Clinical Trial

Inclusion Criteria

  • Adult patients ≥ 18 years old – Adult patients undergoing transfemoral approach TAVR for aortic valve stenosis – Adult patients who are medically eligible to receive both anesthetics (GA and MAC) Exclusion Criteria:

  • Inability to speak English – Body Mass Index (BMI) > 37 kg/m2 – History of difficult airway requiring fiberoptic intubation – Inability to lie flat – Women who are pregnant – Patients who have contraindications to either anesthetic, such as an allergy or history of malignant hyperthermia, will also be excluded from the study. – Inability or unwillingness of subject to give informed consent based on any reason – Patients with any of the following absolute contraindications to TEE: – Perforated Viscus – Esophageal Stricture – Esophageal Tumor – Esophageal Perforation – Esophageal Diverticulum – Active upper GI Bleed

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Medical University of South Carolina
  • Provider of Information About this Clinical Study
    • Principal Investigator: George Whitener, Principal Investigator – Medical University of South Carolina
  • Overall Official(s)
    • George Whitener, M.D., Principal Investigator, Medical University of South Carolina – Department of Anesthesia
  • Overall Contact(s)
    • George Whitener, M.D., 843-876-0758, whiteneg@musc.edu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.